Your browser is no longer supported. Please, upgrade your browser.
Genetron Holdings Limited
Index- P/E- EPS (ttm)-15.42 Insider Own16.03% Shs Outstand91.62M Perf Week-23.41%
Market Cap1.34B Forward P/E- EPS next Y-0.39 Insider Trans0.00% Shs Float27.26M Perf Month-29.49%
Income-473.90M PEG- EPS next Q-0.14 Inst Own24.70% Short Float1.64% Perf Quarter-32.89%
Sales68.00M P/S19.72 EPS this Y-88.10% Inst Trans12.33% Short Ratio1.52 Perf Half Y-38.39%
Book/sh2.69 P/B5.28 EPS next Y35.00% ROA-147.90% Target Price26.12 Perf Year2.16%
Cash/sh2.27 P/C6.25 EPS next 5Y- ROE-173.30% 52W Range9.03 - 31.54 Perf YTD1.43%
Dividend- P/FCF- EPS past 5Y- ROI-14.80% 52W High-54.98% Beta-
Dividend %- Quick Ratio7.20 Sales past 5Y- Gross Margin62.00% 52W Low57.25% ATR1.44
Employees799 Current Ratio7.40 Sales Q/Q19.90% Oper. Margin-70.60% RSI (14)32.84 Volatility12.84% 8.18%
OptionableNo Debt/Eq0.06 EPS Q/Q66.80% Profit Margin- Rel Volume1.67 Prev Close14.69
ShortableYes LT Debt/Eq0.03 EarningsMay 24 BMO Payout- Avg Volume294.09K Price14.20
Recom1.70 SMA20-21.88% SMA50-27.79% SMA200-23.96% Volume492,504 Change-3.34%
Jul-14-20Initiated Canaccord Genuity Buy $19
Jul-14-20Initiated BTIG Research Buy $20
Jul-29-21 04:35AM  
Jul-26-21 06:00AM  
Jul-13-21 08:30AM  
Jul-06-21 04:30AM  
Jul-01-21 10:00PM  
Jun-04-21 06:00AM  
May-24-21 06:45AM  
May-20-21 06:16AM  
May-13-21 06:20AM  
May-10-21 07:00AM  
May-03-21 05:00PM  
Apr-22-21 06:25PM  
Apr-13-21 01:31AM  
Apr-01-21 06:00PM  
Mar-27-21 04:10AM  
Mar-25-21 06:47AM  
Mar-24-21 05:00PM  
Mar-17-21 04:30PM  
Mar-15-21 06:24AM  
Mar-04-21 05:00PM  
Feb-09-21 07:00AM  
Jan-27-21 05:00AM  
Jan-13-21 06:30AM  
Jan-07-21 09:32AM  
Jan-06-21 04:40AM  
Dec-20-20 03:04AM  
Dec-11-20 10:38PM  
Nov-27-20 08:00AM  
Nov-20-20 06:00AM  
Nov-19-20 09:53AM  
Nov-12-20 05:30AM  
Nov-09-20 06:30AM  
Oct-29-20 08:00AM  
Oct-26-20 08:00AM  
Oct-22-20 06:00AM  
Sep-30-20 08:11AM  
Sep-25-20 06:00AM  
Sep-18-20 06:00AM  
Sep-08-20 04:15PM  
Aug-29-20 10:32AM  
Aug-06-20 06:30AM  
Jul-29-20 04:39PM  
Jul-27-20 04:30PM  
Jun-30-20 08:55AM  
Jun-19-20 08:45AM  
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of hepatocellular carcinoma. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1 and TERT gene assays for glioma; Genetron S5 platform, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; and Genetron S2000 platform, a production-scale sequencer. In addition, the company develops ctDNA lung cancer assay for mutations in the epidermal growth factor receptor gene. Further, it offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.